Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

BACKGROUND: Docetaxel has been approved by USFDA as a first-line treatment for castration-resistant prostate cancer (CRPC) patients. Patients receiving androgen deprivation therapy along with docetaxel result in superior survival, lower serum prostate specific antigen (PSA) level, and better quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yu-Ke, Wang, Bi-Juan, Tseng, Jen-Chih, Huang, Shih-Han, Lin, Ching-Yu, Kuo, Ying-Yu, Hour, Tzyh-Chyuan, Chuu, Chih-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864857/
https://www.ncbi.nlm.nih.gov/pubmed/35197069
http://dx.doi.org/10.1186/s12929-022-00797-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864857/
https://www.ncbi.nlm.nih.gov/pubmed/35197069
http://dx.doi.org/10.1186/s12929-022-00797-z

Ejemplares similares